National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Glycerol phenylbutyrate (Ravicti®) which is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs).


NCPE Assessment Process Complete
Rapid review commissioned 26/03/2018
Rapid review completed 20/06/2018
Rapid Review outcome A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Glycerol Phenylbutyrate (Ravicti®) be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement; August 2018